Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2000

View Archived Issues

Sanofi-Synthelabo begins rolling out Xatral XL in Europe

Kosan Biosciences awarded SBIR grant to develop motilin receptor agonists

Maxygen to acquire ProFound Pharma

Atrix to be issued broader U.S. patent for BEMA technology

Isis Pharmaceuticals completes financing with Elan for HCV joint venture

EC-1007: a novel antitumor compound produced by Trichocladium

UCLA describes novel antimicrobial peptides

Novel approach to cell-targeted therapy of HIV designed by Lepetit

Celecoxib: use in inflammatory conditions of the head and neck

Trials demonstrate efficacy, safety and freedom from dependency for novel narcolepsy therapy

Retinamide with superior potency to fenretinide identified by NCI, M.D. Anderson Cancer Center

Subjects with sleep apnea being recruited for multicenter study

Alkylating anthraquinone maintains activity against resistant ovarian cancer cells

Corixa receives U.S. patent on RA vaccine

Antex Biologics makes progress in traveler's diarrhea vaccine

Karolinska Institute and Bristol-Myers Squibb sign cancer pharmacogenomics collaboration

Activella receives U.S. approval for postmenopausal osteoporosis prevention

IGT Pharma adds to neuropharmaceutical patent filings

CPMP recommends approval of Myocet in Europe

FDA approves Mobic for osteoarthritis symptom relief

Patent issued to University of Rochester, setting off heated debate over rights to COX-2 inhibitors

Yakult Honsha profiles novel ACAT inhibitor at major national industry meeting

Tolterodine emerges triumphant from long-term studies supporting the drug as "gold standard"

Promising new treatment approach to gastric cancer involves a modified herpesvirus

Lilly and Ono to collaborate on ARDS therapeutic

U.S. academics discover potential gene therapy for restenosis

Panorama studies CC-1065 analogues with improved anticancer activity, safety

News from FASEB: PST-2744 is a promising treatment for heart failure

Dainippon describes motility-enhancing activity of 5-HT4 receptor agonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...